skip to the content

Clinical Trials

Cervical Cancer Study

GOG 240: A Randomized Phase III Trial of Cisplatin plus Paclitaxel with and without NCI supplied Bevacizumab versus the Non-platinum doublet; Topotecan plus Paclitaxel, with and without NCI supplied Bevacizumab, in stage IV B Recurrent or Persistent Carcinoma of the Cervix

Protocol ID

09-275B

Protocol Description

Chemotherapy with cisplatin and paclitaxel is the standard treatment for cancer of the cervix which is not curable by surgery or radiation.  Cisplatin is the single most effective drug against this kind of cancer.  Paclitaxel is the standard second drug added to cisplatin. In addition to studying the combination of cisplatin plus paclitaxel, other combinations of drugs (eg., topotecan plus paclitaxel), as well as newer drugs (eg., bevacizumab), need to be studied in this disease.

The purpose of this research study is to compare the effectiveness, safety, and the impact on health-related quality of life of four different drug combinations: cisplatin and paclitaxel, cisplatin and paclitaxel plus bevacizumab, paclitaxel and topotecan, as well as paclitaxel and topotecan plus bevacizumab.

Eligibility Criteria

Women with cancer of the cervix

North Shore University Hospital
300 Community Drive
Manhasset, NY 11030
Contact Information: (516) 562-0100

Primary Investigator(s)

  • Veena John, MD

Contact Information

Laureen Thumser, RN
(516) 734-8979
lthumser@nshs.edu

Last Update

May 4, 2010
top
  • Bookmark this Page
  • Toggle Text Size
  • Print this Page
Search Cancer:
top
top